RNTX — Rein Therapeutics Inc

✨ Hidden Gem

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Rein Therapeutics Inc

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.07
Market Cap$89.0M
Float21.3M
Shares Outstanding85.5M
vs. Analyst Target+834.6% to analyst PT
Dividend RateNone
Analyst Target Price$10.00 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$21,157 N/A -$20,333
2021 N/A -$26,164 N/A -$26,484
2022 N/A -$27,329 N/A -$27,478
2023 N/A -$15,732 N/A -$15,229
2024 N/A -$62.9M -$63,000 -$28.0M
2025 N/A -$49.9M -$1,000 -$21.9M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$6.8M
Sep 2025 N/A -$5.6M
Dec 2025 N/A -$32.0M
Mar 2026 N/A -$5.8M

Ownership & Float

Insider Ownership6.8%
Institutional Ownership13.4%
Short Float3.9%
% of All Funds Holding0.54%
Number of Funds Holding44

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$1.28Near-term / short-term trend
Weekly40-Week SMA$1.30Medium-term trend
Weekly80-Week SMA$1.59Cyclical trend (business cycle)
Weekly200-Week SMA$2.40Secular trend (multi-year)
Monthly10-Month SMA$1.30Near-term monthly trend
Monthly20-Month SMA$1.72Medium-term monthly trend
Monthly40-Month SMA$2.19Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.80 resistance 1.63x 16 months ago
$4.30 resistance 1.19x 23 months ago
$6.60 resistance 2.31x 24 months ago

Historical Earnings Reactions (34 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.37% 0.00% 44.12% 7.01% -12.84%
1 Day 0.49% 0.72% 50.00% 24.69% -13.29%
1 Week -1.06% -3.18% 41.18% 35.14% -27.05%
2 Weeks 3.02% -3.20% 41.18% 71.94% -28.92%
1 Month 1.76% -3.06% 41.18% 106.04% -43.81%

Next earnings: May 21, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan17.3%66.7%9
Feb-4.4%33.3%9
Mar0.4%44.4%9
Apr-3.2%33.3%9
May17.7%62.5%8
Jun-13.4%37.5%8
Jul-18.9%11.1%9
Aug12.9%55.6%9
Sep1.8%44.4%9
Oct-6.3%22.2%9
Nov-2.2%22.2%9
Dec-8.6%22.2%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.35% 39.1% 419
Tuesday -0.01% 41.7% 460
Wednesday 0.16% 45.7% 457
Thursday -0.11% 39.0% 449
Friday 0.24% 46.8% 451

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 13.4%

Insider Transactions — Smart Summary

Total insider ownership: 6.8%

12-Month Insider Activity Summary

Total Filings3
Net Value+$25,000
Net Shares Change435,233
% of Float2.0%
C-Suite Filings1
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Voss Capital, LP +$551,043.7 2 2 buy
WINDSOR JAMES BRIAN President and Chief Executive Officer +$25,000 1 1 buy

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-12 WINDSOR JAMES BRIAN President and Chief Executive Officer +$25,000 Transaction at $1.00, now +7.0%
2025-10-28 Voss Capital, LP +$423,450.78 Transaction at $1.38, now -22.7%
2025-11-18 Voss Capital, LP +$127,592.92 Transaction at $1.22, now -12.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Rein Therapeutics Inc (RNTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for RNTX on Trend Edge →